Second‐line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study

BK Link, B Day, X Zhou, AD Zelenetz… - British journal of …, 2019 - Wiley Online Library
Follicular lymphoma (FL) is the second most common lymphoma, and by virtue of its
chronicity, may be the most prevalent and most treated lymphoma in the United States …

Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO …

S Alonso‐Álvarez, L Magnano… - British journal of …, 2017 - Wiley Online Library
The diagnostic criteria for follicular lymphoma (FL) transformation vary among the largest
series, which commonly exclude histologically‐documented transformation (HT) …

Rituximab extended schedule or re-treatment trial for low–tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol E4402

BS Kahl, F Hong, ME Williams… - Journal of Clinical …, 2014 - ascopubs.org
Purpose In low–tumor burden follicular lymphoma (FL), maintenance rituximab (MR) has
been shown to improve progression-free survival when compared with observation. It is not …

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I …

M Shadman, H Li, L Rimsza, JP Leonard… - Journal of Clinical …, 2018 - ascopubs.org
Purpose SWOG S0016 was a phase III randomized study that compared the safety and
efficacy of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and …

[HTML][HTML] The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological …

E Gine, S Montoto, F Bosch, L Arenillas, S Mercadal… - Annals of oncology, 2006 - Elsevier
Background: Histological transformation (HT) is a well-known event in patients with follicular
lymphoma (FL) conferring an unfavorable prognosis. The aim of the study was to analyze …

Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma

PL Zinzani, A Pulsoni, A Perrotti, S Soverini… - Journal of clinical …, 2004 - ascopubs.org
Purpose Promising new therapeutic options for follicular lymphoma (FL) include fludarabine
plus mitoxantrone (FM) and the mouse/human anti-CD20 antibody, rituximab. We performed …

Diagnosis and management of follicular lymphoma: a comprehensive review

R Dada - European journal of haematology, 2019 - Wiley Online Library
Follicular Lymphoma (FL) is an indolent lymphoma and may have various clinical courses.
Worldwide, FL is the second most common non‐Hodgkin lymphoma (NHL) type after diffuse …

Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus 131Iodine-Tositumomab for Previously Untreated …

OW Press, JM Unger, LM Rimsza… - Journal of Clinical …, 2013 - ascopubs.org
Purpose Advanced follicular lymphomas (FL) are considered incurable with conventional
chemotherapy and there is no consensus on the best treatment approach. Southwest …

Improved survival of follicular lymphoma patients in the United States

WT Swenson, JE Wooldridge, CF Lynch… - Journal of Clinical …, 2005 - ascopubs.org
Purpose Despite several new treatment options, single-and multi-institution analyses have
not clarified whether survival patterns in follicular lymphoma (FL) patients have changed in …

R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the …

M Federico, S Luminari, A Dondi, A Tucci… - Journal of Clinical …, 2013 - ascopubs.org
Purpose Although rituximab (R) is commonly used for patients with advanced follicular
lymphoma (FL) requiring treatment, the optimal associated chemotherapy regimen has yet to …